health

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

TL;DR

  • The FDA approved a higher dose of Novo Nordisk's weight loss drug Wegovy.
  • The new dose aims to help Novo Nordisk compete with Eli Lilly's Zepbound, which has shown higher weight loss efficacy.
  • A phase three trial showed the high-dose Wegovy resulted in an average 20.7% weight loss in obese patients over 72 weeks.
  • The standard dose of Wegovy has shown an average of 15% weight loss in clinical trials.
  • The higher dose also demonstrated an average 14.1% weight loss in patients with obesity and Type 2 diabetes.
  • This approval is the first under the FDA's new national priority voucher plan for faster drug reviews.
  • Novo Nordisk expects to launch the higher dose in April.

Weiter zum Originalartikel